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In Italy, a prevalence of 600,000 AF patients 
was estimated for year 2010, and a further 
increase is expected due to the increasing 
age of the population and the improved sur‑
vival of cardiovascular patients [3]. Stroke 
is the main complication of AF [4]: over 
20% of ischemic strokes are linked to some 
INTRODUCTION
Atrial fibrillation (AF) is the most prevalent 
form of arrhythmia, involving about 1‑2% of 
the population in industrialized countries [1]. 
Its prevalence increases with age, reaching 
values above 5% in the over 65 years old, and 
of 9% in octogenarians [2].
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ABSTRACT
OBJECTIVES: The aim of this study was to evaluate the cost‑effectiveness of apixaban in the prevention of thromboem‑
bolic events in patients with non‑valvular atrial fibrillation (NVAF) relatively to standard of care (warfarin or aspirin) from 
the Italian National Health System (SSN) perspective.
METHODS: A previously published lifetime Markov model was adapted for Italian context. Clinical effectiveness data 
were acquired from head‑to‑head randomized trials (ARISTOTLE and AVERROES); main events considered in the model 
were ischemic and hemorrhagic stroke, systemic thromboembolism, bleeds (both major and clinically relevant minor) and 
cardiovascular hospitalizations, besides treatment discontinuations. Expected survival was projected beyond trial duration 
using national mortality data adjusted for individual clinical risks and adjusted by utility weights for health states acquired 
from literature. Unit costs were collected from published Italian sources and actualized to 2013. Costs and health gains 
accruing after the first year were discounted at an annual 3.5% rate. The primary outcome measure of the economic evalua‑
tion was the incremental cost effectiveness ratio (ICER), where effectiveness is measured in terms of life‑years and quality 
adjusted life‑years gained. Deterministic and probabilistic sensitivity analyses (PSA) were carried out to assess the effect 
of input uncertainty.
RESULTS: Apixaban is expected to reduce the incidence of ischemic events relative to aspirin and to improve bleeding 
safety profile when compared to warfarin. Incremental LYs (0.31/0.19), QALYs (0.28/0.20), and costs (1,932/1,104) are 
predicted with the use of apixaban relative to aspirin and warfarin, respectively. The ICERs of apixaban were € 6,794 and € 
5,607 per QALY gained, respectively. In PSA, the probability of apixaban being cost effective relative to aspirin and war‑
farin was 95% and 93%, respectively, for a WTP threshold of € 20,000 per QALY gained. Univariate analyses indicate that 
results were most sensitive to variations of the absolute risk reduction for cardiovascular events with apixaban.
CONCLUSIONS: Apixaban is expected to increase life expectancy and quality‑adjusted life expectancy, but also costs 
dedicated to Italian NVAF patients, as compared to standard of care. The resulting ICERs have high probabilities of be‑
ing below the conventional thresholds of WTP for health benefits of the SSN, indicating efficient allocation of health care 
resources.
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bolic events in the indicated Italian popula‑
tion of patients with NVAF, as compared with 
the standard of care (warfarin for the suitable 
population, aspirin for the remaining).
METHODS
The analysis is conducted as a simulation 
study, performed through the adaptation of 
a previously published international model 
[11,12] simulated using epidemiological, 
clinical practice and unit costs pertinent to 
the Italian setting. The model is designed 
to reproduce the experience of a cohort of 
NVAF patients of user defined features, al‑
ternatively treated with the compared thera‑
peutic options. During the lifetime simula‑
tion, events and consumed resources from 
the Italian National Health System perspec‑
tive are recorded by the model; main clini‑
cal outcomes monitored are ischemic and 
hemorrhagic stroke, systemic thromboem‑
bolism, bleeds (both major and clinically 
relevant minor), cardiovascular hospital‑
izations, and death. Summary effectiveness 
indicators are overall survival, expressed in 
life years (LY), and expected quality‑adjust‑
ed survival, expressed in quality‑adjusted 
life years (QALYs).
Model structure
The model is designed as a decision tree with 
Markov chains as branches; the experience of 
a NVAF patient is discretized in 17 possible 
and mutually exclusive health states (Fig‑
ure 1). Transitions among health states are 
determined by probability matrices derived 
from the relevant literature as detailed else‑
where [11].
At the end of each 6 week cycle, patients can 
stay in the current health state, or experience 
a clinical event and transition to the corre‑
sponding state; some events only imply a re‑
source consumption and a temporary change 
in the utility (quality of life index), whilst oth‑
ers – i.e. stroke, myocardial infarction (MI), 
and systemic embolism – also modify the 
chance of incurring in further events. Stroke 
survivors distribute among subsequent health 
states basing on the assigned severity distri‑
bution of the specific event. Following a ma‑
jor bleeding, patients may continue to receive 
the initial anticoagulant, or switch to a sec‑
ond line treatment, associated with specific 
clinical event risks.
Population
The simulation is run on two cohorts (Table I): 
the first (base‑case) reproducing clinical and 
demographic features of the AVERROES [9] 
and ARISTOTLE [8] trial population, for the 
Figure 1. Simplified structure of the Markov model
form of arrhythmia [1], and in these patients, 
they tend to be more severe than in non‑ar‑
rhythmic patients [5]. About 40% of stroke 
survivors presents moderate to severe dis‑
ability; applying these rates to the prevalent 
population, it has been calculated that around 
384,000 are not autonomous in Italy due to 
stroke, and this figure is expected to rise up 
to 440,000 by 2020 [6].
Therapeutic goals in the management of AF 
patients include symptom control, but also 
the prevention of thromboembolic complica‑
tions, stroke in primis. This was traditionally 
pursued with the administration of vitamin 
K antagonists (VKA), or with antiplatelet 
agents, mainly aspirin, in subjects intolerant 
or contraindicated to VKAs [7].
Apixaban, a direct and selective coagulation 
factor Xa inhibitor, which is associated with 
a more favorable risk/benefit ratio than VKA 
and aspirin [8,9] is facing the launch on the 
market for the thromboembolic prevention 
in non‑valvular AF (NVAF, about 70% of all 
FA cases), with reimbursement restrictions: 
NVAF with both CHA2DS2‑VASc ≥ 1
1 and 
HAS‑BLED > 32 , or TTR < 70% or objec‑
tive difficulties in measuring INR [10].
The objective of the present analysis is the 
evaluation of the cost/effectiveness of the use 
of apixaban in the prevention of thromboem‑
1 Calculates stroke risk for patients with atrial fibrillation, 
possibly better than the CHADS2 score. It is composed of 
7 domains: Age (1 point for ages 65‑74, 2 points for > 74); 
Gender (Female, 1 point); Congestive Heart Failure History 
(Yes, 1 point); Hypertension History (Yes, 1 point); Stroke/
TIA/Thromboembolism History (Yes, 2 points), Vascular 
Disease History (Yes, 1 point), and Diabetes Mellitus (Yes, 
1 point)
2 “HAS‑BLED” is an acronym for: Hypertension, Abnormal 
Liver/Renal Function, Stroke History, Bleeding Predisposi‑
tion, Labile INR, “Elderly” (Age > 65), Drugs/Alcohol Usage, 
with each of the domains scored 1 point if present, to be 
added up to obtain total score, which correlates with the 
risk of major bleeding. Estimates risk of major bleeding for 
patients on anticoagulation to assess risk‑benefit in atrial 
fibrillation care.
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ternatively treated with the compared thera‑
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survivors distribute among subsequent health 
states basing on the assigned severity distri‑
bution of the specific event. Following a ma‑
jor bleeding, patients may continue to receive 
the initial anticoagulant, or switch to a sec‑
ond line treatment, associated with specific 
clinical event risks.
Population
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the first (base‑case) reproducing clinical and 
demographic features of the AVERROES [9] 
and ARISTOTLE [8] trial population, for the 
Figure 1. Simplified structure of the Markov model
analysis of NVAF patients unsuitable and 
suitable for VKA therapy, respectively; the 
second those of a non‑experimental popula‑
tion of NVAF patients studied by Olesen et 
al. [13]. In this cohort study, Olesen et al. 
assessed the individual risk factors compos‑
ing the CHADS2 and CHA2DS2‑VASc score 
calculating the capability of the schemes to 
predict thromboembolism in a nationwide 
cohort of Danish real world patients.
Clinical outcomes rates
The effectiveness and safety profile of apixa‑
ban by VKA suitability reflects event rates 
recorded in the ARISTOTLE [8] and AVER‑
ROES trials [9], integrated with patient‑level 
data made available by Dorian et al. (Table 
II). ARISTOTLE was an international, 
multicentre, double‑blind, double‑dummy, 
placebo‑controlled, randomised controlled 
trial that compared apixaban with warfarin 
in 18,201 adults with atrial fibrillation and 
at least one additional risk factor for stroke, 
assessed by CHADS2 criteria. Apixaban was 
associated with a significantly lower rate of 
stroke and systemic embolism than warfa‑
rin. When strokes were analysed separately, 
apixaban was associated with a significant re‑
duction in hemorrhagic stroke compared with 
warfarin. Episodes of fatal or disabling stroke 
were significantly lower in the apixaban arm. 
The safety analyses point out as apixaban re‑
sulted in significantly fewer bleeding events 
than warfarin for all of the major bleed types 
and clinically relevant non‑major bleeding 
events.
AVERROES study was an international, 
multicentre, double‑blind, double‑dummy, 
placebo‑controlled, randomised controlled 
trial that compared apixaban with aspirin 
in 5,599 adults with atrial fibrillation and at 
least 1 additional risk factor for stroke for 
whom treatment with warfarin was unsuit‑
able or the patients were unwilling to take 
it. Apixaban reduced the rate of stroke and 
Base‑case – 
VKA unsuitable 
population [9]
Base‑case – 
VKA suitable 
population [8]
Real‑world 
population 
[13]
% males 59 65 53
Mean age (years) 70 70 77
CHADS2 score (%)
0‑1 38 34 53
2 35 36 23
> 2 27 30 24
Table I. Baseline characteristics of the simulated populations: base‑case patient 
populations, from AVERROES [9] and ARISTOTLE [8] trials, and alternative‑case 
population, from a nationwide cohort of real world patients, registered in the 
Danish patient registry [13]
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Hemorrhagic strokes (HS) are determined 
as a treatment‑specific percentage of ICHs; 
similarly, their severity distribution, again 
expressed in terms of mRS, is treatment‑spe‑
cific.
IS and HS survivors are at risk of recurrence: 
this is modelled according to a real‑life reg‑
istry indicating a cumulative incidence of 4.1 
and 3.0 per 100 patient‑years, respectively 
[16]; the severity distribution of recurrent 
strokes is conditional on the severity of the 
first stroke, as observed in ARISTOTLE and 
AVERROES.
As with IS and ICH, the model accounts for 
increasing MI risk with higher ages by ap‑
plying an HR of 1.30 per decade [17]. MI 
case fatality rates applied in the simulation 
are specific for gender (10.8% in men and 
15.6 for women), differently than for SE 
(9.4%) [18].
systemic embolism compared with aspirin; 
rates of fatal or disabling stroke were also 
lower in patients who received apixaban. 
When strokes were considered as a separate 
outcome, apixaban decreased the rates of 
ischaemic stroke compared with aspirin but 
did not statistically significantly decrease the 
rates of hemorrhagic stroke.
Increasing age is associated with higher isch‑
emic stroke (IS) risk; in the model, this is 
accounted for by applying a HR of 1.4 per 
decade [14]. Severity distribution of ISs is 
classified according to the modified Rankin 
scale (mRS – mild 0‑2; moderate 3‑4; severe 
5 and fatal 6) specific to the anticoagulant 
(AC) treatment and was derived from pub‑
lished literature (Table II).
Similarly, the model accounts for age‑related 
increase in Intra Cranial Hemorrhages (ICH) 
risk by applying a 1.97 HR per decade [15]. 
VKA suitable VKA unsuitable Second line therapy
Apixaban Warfarin Apixaban ASA ASA (2nd line)
IS* (Rate/100 pts‑yr) 0.98 1.08 1.37 3.10 3.455
Pts distribution (%)
 • Mild mRS (0‑2) 53 45 40 36 364
 • Moderate mRS (3‑4) 21 30 28 38 384
 • Severe mRS (5) 8 10 12 15 154
 • Fatal mRS (6) 18 15 20 11 114
ICH* (Rate/100 pts‑yr) 0.33 0.80 0,34 0,35 0.325
Other ICH (%) 23 36 45 45 454
Case Fatality Rates (%) 132 132 132 132 134
Proportion of HS (%) 77 64 55 55 554
 • Mild mRS (0‑2) 23 20 7 7 74
 • Moderate mRS (3‑4) 32 15 20 20 204
 • Severe mRS (5) 10 12 27 27 274
 • Fatal mRS (6) 35 53 46 46 464
Other MB* (Rate/100 pts‑yr) 1.79 2.27 1,07 0,57 0.895
Case Fatality Rates (%) 22 22 22 22 24
Proportion of GI Bleeds (%) 38 35 35 39 394
CRNM (Rate/100 pts‑yr) 2.08 2.99 3.11 2.37 2.945
MI* (Rate/100 pts‑yr) 0.53 0.61 0.76 0.89 1.115
SE (Rate/100 pts‑yr) 0.09 0.10 0.0 0.41 0.403
Other CV Hosp (Rate/100 pts‑yr) 10.462 10.461 10.46 12.09 13.575
Other Treat Disc (Rate/100 pts‑yr) 13.18 14.41 17.31 19.01 ‑
Background mortality° (Rate/100 pts‑yr) 3.08 3.34 2.97 3.59 ‑
Table II ‑ Summary of main clinical inputs used in the analysis [11]
CRNM: Clinically Relevant non Major Bleeds; GI: GastroIntestinal Bleeds; HS: Hemorrhagic Stroke; ICH: IntraCranial Hemorrhages; IS: Ischemic 
Stroke; MI: Myocardial Infarction; Other CV Hosp: Other CardioVascular Hospitalization; Other MB: Other Major Bleeds; Other TreatDisc: Other 
Treatment Discontinuation; pts: Patients; SE: Systemic Embolism; yr: year
1 Assumption (same rate as the apixaban’s rate observed among the VKA unsuitable population);
2 Pooled sample percentages;
3 Assumption (same rate as ASA first line observed in the VKA unsuitable population)
4 Assumption (same distribution as ASA first line)
5 Subgroup of patients who had VKA‑unsuitability “demonstrated” (i.e., previously failed warfarin)
* Stroke, bleeds and MI risks are adjusted over time to take into account the increased risks with aging: HR for adjunctive decade of 1.4 [14], 1.97 
[15], and 1.3 [17], respectively, are applied
° For the duration of the trial period (1.9 years (ARISTOTLE) and 1.2 years (AVERROES))
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for each severity category within ischemic 
and hemorrhagic strokes, the mean long‑term 
maintenance cost has been approximated 
to the monthly cost recorded in the second 
semester; the costs for the acute phase cor‑
respond to the sum of the corresponding 
DRG tariff [32] and the difference between 
the costs accrued in the first and second fol‑
low‑up semester.
For acute and long‑term MI management, 
cost data are elaborated basing on three‑year 
follow‑up data reported for Italian MI sur‑
vivors [33]. The costs attributed to the other 
clinical events considered are equaled to the 
During the simulation, patients may dis‑
continue treatment, either completely, or by 
switching to another AC regimen, as a con‑
sequence of clinical events incurred, or for 
other reasons, as described on Dorian et al. 
[11] and Lip et al. [12].
Besides the already described case fatality 
rates for stroke, bleeding, and MI, the popu‑
lation is subjected to a background mortal‑
ity derived from ARISTOTLE for the dura‑
tion of the trial follow‑up; given the lack of 
sound comparative mortality rates, the same 
background mortality has been applied to all 
NOACs.
Beyond the trial duration, mortality is pro‑
jected based on Gompertz distributions fitted 
on Italian age‑ and gender‑specific popula‑
tion rates [19], corrected for the HRs associ‑
ated to AF, MI, stroke, and SE, as shown in 
Table III.
Utility
Baseline utility assigned to the simulated 
population derives from a preference study 
conducted on AF patients [25]. The model 
accounts for reduced preference for warfarin 
and ASA administration, as reported in Gage 
et al. [26]; temporary disutilities are assigned 
to patients experiencing clinical events, as 
shown in Table IV.
Costs
Costs are evaluated from the perspective of 
the National Health System (SSN); accord‑
ingly, only direct health care costs are con‑
sidered:
 ‑ Drug acquisition costs, at negotiated net 
prices [27] (Table V);
 ‑ Routine visits [28] for all treated patients 
and INR monitoring for warfarin treated 
patients, basing on data reported by Pen‑
go in 2011 [29] and Mennini in 2012 [30];
 ‑ Acute event management (strokes, 
bleeds, myocardial infarction, and other 
CV hospitalizations);
 ‑ Long‑term post‑event management for 
stroke, MI, and SE;
 ‑ Other health care costs associated with 
AC management (Table VI).
Stroke management costs have been elabo‑
rated basing on data reported in an observa‑
tional study conducted on 411 Italian stroke 
survivors, followed up for 12 months [31]: 
Health 
condition
NVAF [20]
Stroke [21‑23] MI [24]
SE°
Mild Moderate Severe Female Male
HR 1.34 3.18 5.84 15.75 4.16 2.56 1.34
Table III. Death hazard ratios according to the health condition of the simulated patient
° Assumption
Condition Mean utility Disutility (duration)
Atrial fibrillation (Baseline) 0.7270 [25]
Ischemic stroke
Mild 0.6151 [25]
Moderate 0.5646 [25]
Severe 0.5142 [25]
Hemorrhagic stroke
Mild 0.6151 [25]
Moderate 0.5646 [25]
Severe 0.5142 [25]
Myocardial infarction 0.6098 [25]
Systemic embolism 0.6265 [25]
Other intracranial 
hemorrhages
‑0.1511 [25] (6 weeks [11,12])
Other major bleeding ‑0.1511 [25] (14 days)*
Clinical relevant,  
non major bleeds
‑0.0582 [25] (2 days)*
Other CV hospitalizations ‑0.1276 [25] (6 days [11,12])
Drug utilization
Aspirin ‑0.0020 [26]
Warfarin ‑0.0120 [26]
Table IV. Utilities and disutilities used in the simulation
* Assumption based on Freeman, 2011 [17] and reported on Dorian, 2014 [11] and Lip, 
2014 [12]
Drug Dose (mg/die) Daily cost (€)
Aspirin 100 0.04
Warfarin 5 0.03
Apixaban 10 1.90
Table V. Drug acquisition costs, at negotiated net prices [27]
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The effect of parameter uncertainty on the 
results is assessed by probabilistic sensitiv‑
ity analyses (PSA), in which the model is 
re‑evaluated with 2000 sets of parameter val‑
ues sampled from appropriate distributions. 
The influence of single parameters on the 
results is evaluated with a series of one‑way 
deterministic sensitivity analyses (DSA), in 
which the model is re‑calculated using ex‑
treme parameter values, corresponding to the 
lower and upper limits of the 95% confidence 
interval; when this was unavailable from the 
original data, it has been calculated assuming 
a SEM equaling 25% of the mean.
In incremental cost/effectiveness analyses, 
costs and benefits accruing after the first year 
are discounted at a 3.5% annual rate.
corresponding DRG‑based tariff [32] paid to 
the hospitals by the SSN.
Other AC related costs considered are related 
to dyspepsia management (€ 71.46/year [34], 
rates of dyspepsia from ARISTOTLE for 
apixaban and warfarin).
All historical cost data have been actualized 
to 2013 values using official indices [19].
Incremental cost/
effectiveness analysis
Lifetime results from the simulation are pre‑
sented as incremental cost/effectiveness and 
incremental cost/utility ratios, i.e. as the ratio 
of the difference in costs over the difference 
in life years and quality‑adjusted life years, 
respectively.
Unit cost (€) Unit Duration Source
INR monitoring 380 per year N/A Mennini et al. [30]
Routine visit 15.37 per visit N/A Lucioni et al. [28]
Ischemic Stroke
Mild
 • Acute 4,663.06 per episode 2 weeks Fattore et al. [31]
 • Maintenance 81.76 per month Lifetime Fattore et al. [31]
Moderate
 • Acute 6,137.96 per episode 2 weeks Fattore et al. [31]
 • Maintenance 139.04 per month Lifetime Fattore et al. [31]
Severe
 • Acute 10,311.34 per episode 2 weeks Fattore et al. [31]
 • Maintenance 327.95 per month Lifetime Fattore et al. [31]
Fatal 3,891.00 per episode N/A DRG 14 [32]
Hemorrhagic stroke
Mild
 • Acute 6,321.14 per episode 2 weeks Fattore et al. [31]
 • Maintenance 118.11 per month Lifetime Fattore et al. [31]
Moderate
 • Acute 10,073.43 per episode 2 weeks Fattore et al. [31]
 • Maintenance 200.86 per month Lifetime Fattore et al. [31]
Severe
 • Acute 20,932.42 per episode 2 weeks Fattore et al. [31]
 • Maintenance 473.77 per month Lifetime Fattore et al. [31]
Fatal 3,891 per episode N/A DRG 14 [32]
Other ICH 25,812 per month N/A DRG 528 [32]
Other major bleeding 3,317 per episode N/A DRG 174 [32]
CRNMB 2,091 per episode N/A DRG 175 [32]
IM
 • Acute 6,275.21 per episode N/A Mantovani et al. [33]
 • Maintenance 157.97 per month Lifetime Mantovani et al. [33]
SE
 • Acute 4,663.06 per episode 2 weeks Assumption
 • Maintenance 81.76 per month Lifetime Assumption
Other CV hospitalization 4,742 per episode N/A DRG 479 [32]
Table VI. Cost inputs
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ischemic events when compared to aspirin. 
In the comparison against warfarin in the rel‑
evant population, apixaban is associated with 
an estimated improved bleeding safety profile.
When converted into the summary indicators 
(Table VIII) used for the incremental allocation 
Events on total population (n.)
VKA unsuitable VKA suitable
Apixaban Aspirin Apixaban Warfarin
Ischemic Stroke 268 317 238 241
Recurrent Ischemic Stroke 33 44 29 30
Hemorrhagic Stroke 21 19 27 41
Recurrent Hemorrhagic Stroke 1 1 2 2
Systemic Embolism 26 37 26 26
Other ICH 17 15 13 25
Other Major Bleeds 111 76 171 187
Clinically Relevant Non‑Major Bleeds 344 273 298 341
MI 100 97 88 90
Other CV Hospitalization 1,231 1,189 1,231 1,200
Other Treatment Discontinuation 709 675 645 641
Table VII. Clinical events among 1,000 VKA unsuitable and VKA suitable patients over lifetime
Lifetime result Delta  
(apixaban ‑ 
comparator)
ICER  
(apixaban vs. 
comparator)Apixaban Apixaban ASA
VKA suitable
Total cost (€) 14,133 13,029 1,104
QALY 6.48 6.28 0.20 5,607
LY 9.12 8.93 0.19 5,814
VKA unsuitable
Total cost (€) 14,215 12,283 1,932
QALY 6.45 6.17 0.28 6,794
LY 9.10 8.79 0.31 6,177
Table VIII. Base‑case CEA: accrued LYs, QALYs, total costs, and corresponding ICERs
Figure 2. DSA apixaban vs. warfarin. The extreme values tested for each parameter are reported on the same line of the corresponding bar
RESULTS
In Table VII, the expected clinical events ac‑
cruing in two hypothetical populations of 
NVAF patients over lifetime are presented. 
According to the clinical trials’ results, apixa‑
ban is expected to reduce the incidence of 
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influential parameters are the absolute CV 
risks for both treatments and the ICH risk as‑
sociated with warfarin use; in any tested case, 
the corresponding ICER remains below com‑
monly accepted WTP values.
The same considerations hold true for the 
comparison against ASA, where ICER is 
most influenced by variations of the attribut‑
ed stroke risks for both treatments, and by the 
level of CV risk for apixaban‑treated patients 
(Figure 3).
Probabilistic sensitivity analysis substantially 
confirms the findings of the main analysis, as 
shown in Figure 4 representing the distribu‑
tion of the 2000 ICER estimates of the PSA.
Apixaban is expected to be a better choice 
than warfarin for any WTP above about 
10,000 €/QALY gained, with probabilities of 
being cost‑effective of 93% and 96%, for the 
conventional WTP thresholds of 20,000 and 
30,000 €/QALY gained, respectively. Cor‑
Figure 3. DSA apixaban vs. ASA. The extreme values tested for each parameter are reported on the same line of the corresponding bar
Figure 4. PSA: scatterplots of ICERs of apixaban vs. warfarin in patients VKA suitable (panel A) and ASA in patients VKA unsuitable (panel 
B). The two lines represent WTP thresholds: 20,000 and 30,000 €/QALY gained (lower and upper, respectively). The diamonds indicate 
the base case ICER Figure 5. Probability of being the most cost‑effective treatment choice in VKA suitable (panel A) and VKA unsuitable (panel B) patients
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Apixaban is expected to be a better choice 
than warfarin for any WTP above about 
10,000 €/QALY gained, with probabilities of 
being cost‑effective of 93% and 96%, for the 
conventional WTP thresholds of 20,000 and 
30,000 €/QALY gained, respectively. Cor‑
Figure 3. DSA apixaban vs. ASA. The extreme values tested for each parameter are reported on the same line of the corresponding bar
Figure 4. PSA: scatterplots of ICERs of apixaban vs. warfarin in patients VKA suitable (panel A) and ASA in patients VKA unsuitable (panel 
B). The two lines represent WTP thresholds: 20,000 and 30,000 €/QALY gained (lower and upper, respectively). The diamonds indicate 
the base case ICER Figure 5. Probability of being the most cost‑effective treatment choice in VKA suitable (panel A) and VKA unsuitable (panel B) patients
efficiency analyses, the above figures translate 
into a gain of 0.19 LYs, or 0.20 QALYs, and 
of 0.31 LYs, or 0.27 QAYs, in the compari‑
son against aspirin and warfarin, respectively. 
This improvement comes at an increased cost, 
which however, seems moderate, equaling 
around € 1,000 and 2,000 per patient over a 
lifetime, respectively. In terms of incremental 
cost/effectiveness, this corresponds to 5,600 
€/QALY or 5,800 €/LY gained and € 6,800/
QALY or € 6,200/LY gained, respectively.
These ICERs indicate a favourable pharma‑
coeconomic profile, when assessed in terms 
of the willingness to pay for health benefits 
of the SSN, or of any other third party payer 
in industrialized countries.
DSA for the analysis of apixaban vs. war‑
farin is represented as a tornado diagram in 
Figure 2, showing the impact of single pa‑
rameters on the estimated ICERs in order 
of decreasing magnitude of effect. The most 
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